ImmuPharma (LON:IMM) Shares Down 5.6% – Should You Sell?

ImmuPharma plc (LON:IMM)’s share price traded down 5.6% on Thursday . The stock traded as low as GBX 2.42 ($0.03) and last traded at GBX 2.53 ($0.03). 685,774 shares were traded during mid-day trading, a decline of 91% from the average session volume of 7,771,297 shares. The stock had previously closed at GBX 2.68 ($0.04).

ImmuPharma Price Performance

The stock has a market capitalization of £10.34 million, a price-to-earnings ratio of -4.21 and a beta of 1.53. The company’s 50-day simple moving average is GBX 2.76 and its 200-day simple moving average is GBX 2.83.

ImmuPharma (LON:IMM) last announced its earnings results on Monday, May 19th. The company reported GBX (0.60) (($0.01)) earnings per share for the quarter. ImmuPharma had a negative return on equity of 131.41% and a net margin of 3,519.56%. Research analysts expect that ImmuPharma plc will post -339.0000022 earnings per share for the current year.

About ImmuPharma

ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.